Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases

Pharmacology, Toxicology and Pharmaceutical Science

• Nitric Oxide Synthase Inhibitor 100%
• Neuronal Nitric Oxide Synthase 100%
• Amino Acid 100%
• Degenerative Disease 100%
• Rabbit Model 66%
• Bioavailability 66%
• Isoenzyme 66%
• Drug Development 33%
• Lead Compound 33%
• Dipeptide 33%
• Nerve Degeneration 33%
• Cerebral Palsy 33%
• Disease 33%
• Carboxamide 33%
• Blood-Brain Barrier 33%

Keyphrases

• Neurodegenerative Diseases 100%
• Neuronal Nitric Oxide Synthase (nNOS) 100%
• Selective Neuronal Nitric Oxide Synthase Inhibitors 100%
• Selective Inhibitor 50%
• Amino Acids 33%
• Rabbit Model 33%
• Isozymes 33%
• Second-sphere 33%
• First-in-class 16%
• Cerebral Palsy 16%
• Neurodegeneration 16%
• Dipeptide 16%
• Active Sites 16%
• Drug Design 16%
• Science Questions 16%
• Inhibitor Design 16%
• Amides 16%
• Endothelial Nitric Oxide Synthase (eNOS) 16%
• General Applications 16%
• Blood-brain Barrier Penetration 16%
• De-novo Design 16%
• Neurobehavioral Symptoms 16%
• Fragment-based 16%
• Nonapeptides 16%
• Amino Acid Variation 16%
• Structure Modification 16%
• Metics 16%
• Fragment Hopping 16%

Neuroscience

• Neurodegenerative Disorder 100%
• Amino Acid 100%
• Neuronal Nitric Oxide Synthase 100%
• Isoenzyme 66%
• Cerebral Palsy 33%
• Blood Brain Barrier 33%
• Dipeptide 33%
• Neurodegeneration 33%
• Carboxamide 33%